CAD/EUR
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
VCNX
Vaccinex, Inc.
In-person and virtual Presentation: November 10-14th, 2021
ROCHESTER, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Dr. Elizabeth Evans, PhD, Chief Operating Officer and SVP, Discovery and Translational Medicine, will present Poster #434, Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84), at the Society for Immunology of Cancer's (SITC) 36th Annual Meeting being held from November 12th - 14th in Washington D.C. Please see Presentation details below:
SITC Conference Information
Session Title:
Clinical Trials in Progress, Poster Session
Poster #: Title
Poster #434: Phase 1/2 study to evaluate pepinemab in combination with pembrolizumab in advanced, recurrent or metastatic head and neck cancer (KEYNOTE B84)
https://ir.vaccinex.com/node/8411/ics
Program Link:
https://sitc.sitcancer.org/2021/abstracts/titles/index.php?filter=Keynote+B84
The Poster will be presented in-person 12:30 -2 and 7 - 8:30 p.m. ET on Saturday, November 13, and on the SITC 2021 virtual meeting platform from 7 a.m. ET on Friday, November 12, 2021, until the virtual meeting platform is closed on January 9, 2022. The Poster will also be available on Vaccinex's website starting on November 12, 2021, at: https://ir.vaccinex.com/presentations
For more information about the SITC Annual Meeting please refer to the conference website. The in-person program in Washington D.C. will be streamed live on the digital platform.
About Vaccinex, Inc.
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain, is currently being evaluated in the clinic as a treatment for head & neck cancer and Alzheimer's disease, with ongoing exploration of potential phase 3 development in Huntington's disease. The company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors including GPCR and ion channels.
To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. ("Vaccinex," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our clinical trials of pepinemab in various indications, the use and potential benefits of pepinemab in Huntington's and Alzheimer's disease and other indications, and other statements identified by words such as "may," "will," "appears," "expect," "planned," "anticipate," "estimate," "intend," "hypothesis," "potential," "suggest", "advance," and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled "Risk Factors" in our periodic reports filed with the Securities and Exchange Commission ("SEC") and the other risks and uncertainties described in the Company's Form 10-K for year-end December 31, 2020, and subsequent filings with the SEC.
John Mullaly
jmullaly@lifesciadvisors.com
Omineca Grants Stock Options
Omineca Mining and Metals Ltd. (TSXV: OMM) ("Omineca") announces the grant of 1,300,000 stock options pursuant to its stock option plan. 300,000 of the options were granted to directors and executive officers, with the balance granted to consultants. The options are exercisable at $0.20 per share and, if not exercised, expire January 13, 2027, subject to earlier expiration in accordance with the stock option plan and the applicable policies of the TSX Venture Exchange.
Aritzia (TSX:ATZ) Surged 20% Last Week: Should You Buy it Now?
Aritzia Inc. (TSX:ATZ) is a clothing stock that has gained serious momentum over the past year. Is it too late to buy in? The post Aritzia (TSX:ATZ) Surged 20% Last Week: Should You Buy it Now? appeared first on The Motley Fool Canada.
Group: Tax rich to fund vaccines for poor hit by pandemic
LONDON (AP) — Anti-poverty organization Oxfam called Monday for governments to impose a one-time 99% tax on the world's billionaires and use the money to fund expanded production of vaccines for the poor — part of an effort to combat global inequality widened by the coronavirus pandemic. The ranks of the super-rich have swelled during the pandemic thanks to ample financial stimulus that pumped up stocks, the group said. Meanwhile, poor countries have suffered more than their share from COVID-19
15 Top Stock Picks for 2022
We asked our Foolish writers for their top ideas for 2022. Here are their picks. The post 15 Top Stock Picks for 2022 appeared first on The Motley Fool Canada.
1 Important RRSP Update for 2022
The RRSP contribution limit for 2022 remains at 18% of a user's earned income, although the dollar amount is higher than in 2021. The post 1 Important RRSP Update for 2022 appeared first on The Motley Fool Canada.
2021 home sales set new record, tops previous high by 20 per cent: CREA
The Canadian Real Estate Association says annual home sales reached a new high in 2021, eclipsing the previous record set in 2020 by about 20 per cent. The association said Monday that about 667,000 residential properties changed hands in 2021, about 30 per cent more than the 10-year average. However, home sales in December were little changed from November and were coupled with a dearth of properties on the market that was so extreme that CREA senior economist Shaun Cathcart called it a record
The dollar edged higher on Monday as traders continued to hold on to dollars but took the view that Federal Reserve tightening plans were largely priced in, while the euro eased from Friday's two-month high. An unexpected cut to key lending rates in China highlighted it as the outlier, with other major central banks in talks to raise rates. China's move only briefly weighed on the yuan.
BOSTON (AP) — Microsoft said late Saturday that dozens of computer systems at an unspecified number of Ukrainian government agencies have been infected with destructive malware disguised as ransomware, a disclosure suggesting an attention-grabbing defacement attack on official websites was a diversion. The extent of the damage was not immediately clear. The attack comes as the threat of a Russian invasion of Ukraine looms and diplomatic talks to resolve the tense stand-off appear stalled. Micros
'Big win': Renewable diesel, canola-crushing plant to be built in Regina
REGINA — Federated Co-operatives Ltd. says a new renewable diesel fuel and canola-crushing plant will be part of its plan to reduce greenhouse gas emissions. The oil-production business announced Monday that the estimated $2-billion Integrated Agriculture Complex is to be built in north Regina near the company's Co-op refinery and in partnership with global pulse-processor and supplier AGT Foods. Federated Co-operatives CEO Scott Banda said his company has made a commitment to reduce its greenho